Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 11—November 2004

Research

Histopathologic Improvement with Lymphedema Management, Léogâne, Haiti

Susan F. Wilson*, Jeannette Guarner*, Alix L. Valme†, Jacky Louis-Charles†, Tara L. Jones*, and David G. Addiss*Comments to Author 
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hôpital Ste. Croix, Léogâne, Haiti

Main Article

Table 4

Demographic, physical, and treatment-related characteristics of 27 patients with initial and follow-up skin biopsy specimens, by degree of histologic improvement (involving >4 vs. <4 histologic characteristics), Léogâne, Haiti

Factors examined Improvement in >4 
histologic characteristics Improvement in <4 
histologic characteristics
Number of patients 11 16
Female (%) 9 (82) 11 (69)
Median age, y (range) 39 (20–61) 32 (16–61)
Stage of lymphedema (%)
  Stage 1 2 (18) 0 (0)
  Stage 2 5 (45) 13 (81)
  Stage 3 4 (36) 3 (19)
Median no. of days in lymphedema management before 
1st biopsy (range) 21 (0–432) 19.5 (0–468)
Median no. of days between biopsies (range) 359 (317–503) 366 (317–656)
Median annual incidence of ADLA between biopsies (range) 0 (0–2) 0 (0–3)
Median duration of lymphedema, y (range) 11.5 (4–27) 7 (0–25)

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO